€15.06
Your prediction
Financial data and news for Intellia
sharewise wants to provide you with the best news and tools for Intellia, so we directly link to the best financial data sources.
Financials
News
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
Key Points
- Interested in BioCryst Pharmaceuticals, Inc.? Here are five stocks we like better.
- BioCryst reaffirmed full-year ORLADEYO revenue guidance of $625 million to $645 million and
3 Biotech Stocks That Could Benefit from the Patent Cliff
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.
A key reason for this activity is
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan
This Stock Is Up 58% This Year. Is It too Late to Buy?
Intellia Therapeutics (NASDAQ: NTLA), a clinical-stage biotech company, did not start the year on a strong note. The company was dealing with regulatory issues: The U.S. Food and Drug Administration
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Tuesday was a rough day for Shopify (NASDAQ: SHOP), Intellia Therapeutics (NASDAQ: NTLA), and GeneDX Holdings (NASDAQ: WGS) investors. All three growth stocks tumbled between 4% and 49%. As the
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics (NASDAQ:
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood seems to always be making market moves. The founder and CEO of Ark Invest publishes her transactions at the end of every trading day, and that gives us all a great way to track one of
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
On Jan. 5, John M. Leonard, the president and CEO of Intellia Therapeutics (NASDAQ:NTLA), executed an open-market sale of 34,146 directly held shares, totaling $314,484.66, as disclosed in a SEC